CDKN2A and lung carcinoma: In clinical lung cancer samples (n = 49), the prevalence of homozygous loss of MTAP‐CDKN2A was 12.2% (6/49) (Figure 2C); and 83.3% (5/6) of these samples also had EGFR co‐mutation (Figure S1A).